FibroGen Stock Discussion

$FibroGen(FGEN.US)$ FibroGen Announces Presentation of Positive Interim Data From the Phase 1B Study of FG-3246 (for46) in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) at the 2024 American Society of Clinical Oncology Annual Meeting

$FibroGen(FGEN.US)$ Upcoming Milestones:
Pamrevlumab
•Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in mid-2024, reflecting PanCAN’s updated timing to complete database lock and subsequent analysis of the topline results by the independent Statistical Monitoring Committee.•Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic can...

$FibroGen(FGEN.US)$ 👀

$Clearmind Medicine(CMND.US)$ $FibroGen(FGEN.US)$ $reAlpha Tech(AIRE.US)$ $MMTEC Inc(MTC.US)$ $Peloton Interactive(PTON.US)$
📊⚡️📊

$FibroGen(FGEN.US)$
NEWS
FibroGen Reports First Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) reported strong financial results for Q1 2024, showing a 55% year-over-year net revenue growth driven by roxadustat sales in China and one-time revenue from the termination of the US/RoW AstraZeneca agreement. The company has a healthy cash balance of $214.7 million, ensuring financial stability till 2026.
55% year-over-year net revenue growth in Q1 2024.
Robust roxadustat sales in China ...

$FibroGen(FGEN.US)$
NEWS
FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

📣 Ahead of AACR24, which starts this Friday, 🔬
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US)$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US)$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US)$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US)$ : Nana-val ▻ Ph3 ▻ Lymphoma

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$Hutchmed (China)(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

$FibroGen(FGEN.US)$ 👀😎